| Project/Area Number |
25293340
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Shinshu University |
|---|
Principal Investigator |
SHIOZAWA Tanri 信州大学, 学術研究院医学系, 教授 (20235493)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUZUKI Akihisa 信州大学, 医学部附属病院, 特任研究員 (10547095)
ASAKA Ryoichi 信州大学, 医学部附属病院, 助教 (00623688)
ANDO Hirofumi 信州大学, 医学部附属病院, 助教 (80722925)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2015: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
|---|
| Keywords | 子宮内膜癌 / サイクリンA / 分子標的薬 / 低分子化合物 / prohibitin |
|---|
| Outline of Final Research Achievements |
Since the number of endometrial carcinoma (EC) patients is sharply increasing in Japan, development of new therapeutic strategies is mandatory. We previously found the increased expression of cyclin A, a cell-cycle regulatory molecule, to be correlated with poor prognosis of EC patients. Therefore, we considered cyclin A to be a important therapeutic target. After screening of a library containing more than 10,000 low molecular weight compound, we found that a molecule with 300 Da (termed “X” ) had strongly suppressed the transcription of cyclin A and growth of EC xenografts on mice, suggesting “X” to be a promising lead compound. In order to improve the function of “X”, we examined the working mechanism of “X”, and found X to bind to a transcriptional factor, prohibitin. Thus, prohibitin-oriented structural modification seems to pave the way for a new drug development.
|
